Tixagevimab-cilgavimab v preexpoziční profylaxi a léčbě onemocnění COVID-19

Abstract

For more than two years, COVID-19 caused by SARS-CoV-2 represents a life-threatening global pandemic disease that contributes to high mortality. Elderly individuals with comorbidities and immunocompromised patients are particularly at risk. Therefore, scientific research efforts are focused on the intensive development and optimization of new treatments for COVID-19. Early treatment with certain SARS-CoV-2-neutralizing monoclonal antibodies has been shown both “in vitro” and in clinical practice to be effective in patients at high risk of disease progression to severe COVID-19 and death. Our review summarizes the potential clinical benefits of the recently approved combination of monoclonal antibodies tixagevimab and cilgavimab for prevention and treatment of COVID-19.